NanoCarrier and JCR conclude collaborative research agreement for drug delivery to the brain for nucleic acid medicines
Oct 10 (Reuters) - JCR Pharmaceuticals Co Ltd <4552.T>:* Says it and NanoCarrier Co., Ltd <4571.T> conclude collaborative research agreement for drug delivery to the brain for nucleic acid medicines .* Under this agreement, Nanocarrier and JCR will integrate the unique technologies and knowledge of both companies, and aim to develop an innovative drug effectively delivered to the brain .
Latest Developments forJCR Pharmaceuticals Co Ltd
- JCR Pharmaceuticals initiates phase 3 clinical trial of JR-141 for Hunter Syndrome
- JCR Pharmaceuticals initiates phase 2 clinical trial of JR-141 for hunter syndrome in Brazil
- JCR Pharmaceuticals to recall partial sleep apnea alarm products
- JR-131, long-acting erythropoiesis-stimulating agent, demonstrates equivalence in phase III study